Abstracts tagged "Fibromyalgia and severity"

Abstract Number: 1120 • 2014 ACR/ARHP Annual Meeting
The Relationship Between Tender Points and Disease Severity in Patients with Fibromyalgia
Oya Ozdemir¹ and Fitnat Dincer², ¹Department of Physical Medicine and Rehabilitation, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department Of Physical Medicine and Rehabilitation, Hacettepe University, Faculty of Medicine, Ankara, Turkey
Background/Purpose: The aim of this study was to investigate the relationship between tender point examination and disease severity in patients with a diagnosis of fibromyalgia…
Abstract Number: 2851 • 2013 ACR/ARHP Annual Meeting
The Polysymptomatic Distress Scale As a Measure Of Disease and Practice Severity In Fibromyalgia
Frederick Wolfe¹, Don L. Goldenberg², Brian T. Walitt³ and Winfried Häuser⁴, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Rheumatology, Newton-Wellesley Hosp, Newton, MA, ³Rheumatology, Washington Hospital Center, Washington, DC, ⁴Klinikum Saarbrücken, Saarbrücken, Germany
Background/Purpose: The 2010 American College of Rheumatology (ACR) fibromyalgia (FM) criteria created a scale for the measurement of severity of pain extent—the 0-19 Widespread Pain…
Abstract Number: 119 • 2013 ACR/ARHP Annual Meeting
Routine Assessment Of Patient Index Data 3 In Fibromyalgia: A Rapid and Reliable Instrument For Evaluating Disease Severity?
Ece Kaptanoglu, Ozlem Sahin, Yunus Durmaz, Ahmet Kivanc Cengiz and Sami Hizmetli, Rheumatology, Cumhuriyet University, Sivas, Turkey
Background/Purpose: Routine Assessment of Patient Index Data 3 (RAPID 3) is a patient based questionnaire which was designed for evaluation of disease activity without formal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].